PharmaFocus Today – Page 13 – media

RNA editing pioneers fought a comeback

This is the title of an article published in Nauter in February this year (Move over, CRISPR: RNA-editing therapies pick up steam). RNA editing technology, which is coming to the fore, is seen as a potential to surpass CRISPR due to its safer and more flexible characteristics. The technology is in its infancy, and the bets of MNCs such as Eli Lilly and GSK have once pushed its popularity to a climax. However, Wave, an RNA editing pioneer founded in 2012, took more than 10 years to push its first RNA editing project WVE-006 into clinical trials. During this period, due to the clinical failure of other nucleic acid drugs, Wave’s stock price fell from a high of US$56 per share to around US$1 per share, and market expectations were no longer met. After years of silence, a counterattack driven by clinical data is taking place. On October 16, Wave ...
- Source: drugdu
- 70
- October 19, 2024
Suda Testing participates in the release of ESG standards for medical device companies, promoting sustainable development in the industry

On the morning of October 14, sponsored by the “the Belt and Road” Life Science and Technology Promotion Alliance, and jointly organized by the Shenzhen Life Science and Technology Industry University Research Capital Alliance, Suzhou Suda Health and Environmental Technology Research Institute Co., Ltd., Shenzhen Huada Intelligent Manufacturing Technology Co., Ltd., and Jiewen (Shenzhen) Technology Services Co., Ltd., the ESG standard seminar for the medical device industry was successfully held in Shenzhen. The purpose of this seminar is to jointly explore the current situation and challenges of ESG standards in the medical device industry, promote the formulation and implementation of standards, and enhance the industry’s international competitiveness and sustainable development capabilities. At the beginning of the meeting, relevant leaders from the Standards Department of Shenzhen Municipal Market Supervision Administration, Suzhou Medical Device Industry Development Group Co., Ltd., the “the Belt and Road” Life Technology Promotion Alliance, and Suzhou Suda Health ...
- Source: drugdu
- 60
- October 19, 2024
2.5 billion! Haoluo Jie has obtained the world’s only uterine ablation product

On October 15th, Hologic Corporation (hereinafter referred to as Hologic) announced that it had reached a final acquisition agreement with Gynesonics for approximately $350 million (approximately RMB 2.5 billion). With this acquisition, Haoluo Jie will further expand its layout in women’s health products to consolidate its leading position in global women’s health. Acquiring innovative products The Gynesonics company acquired this time is an innovative women’s healthcare company headquartered in California, USA. Since its establishment in 2005, we have been committed to providing safe and effective minimally invasive treatment solutions for women with symptomatic uterine fibroids. The Sonata system, the core product of Gynesonics, is the world’s first and only FDA approved diagnostic intrauterine imaging device that can treat specific symptomatic uterine fibroids, including fibroids associated with severe menstrual bleeding, through the cervix. This is also the purpose of Haoluo Jie’s huge investment in acquisition.  The Sonata system consists of ...
- Source: drugdu
- 57
- October 19, 2024
GLP-1 Can Improve Opioid Addiction Issues

A recent study indicates that Novo Nordisk’s Ozempic and similar GLP-1 medications may reduce patients’ misuse of opioids and alcohol, further demonstrating the broad potential of GLP-1 drugs beyond treating obesity and diabetes. This study was published on Thursday, October 17, in the journal *Addiction*. The research aims to further explore the growing potential uses of GLP-1 and seeks to address the troubling issue of opioid addiction among patients. An analysis conducted on 500,000 opioid-addicted patients revealed that those using GLP-1 medications had a 40% lower rate of opioid overdose compared to those who did not take GLP-1 medications. Additionally, similar comparative research was conducted among alcoholics. The results showed that among over 5,000 alcoholics using GLP-1 drugs, the rate of excessive drinking was 50% lower compared to those not using GLP-1. New Treatment Options The lead researcher, Dr. Fares Qeadan, an associate professor of biostatistics at Loyola University Chicago, ...
- Source: drugdu
- 63
- October 18, 2024
Bankruptcy and divestment, breathing giant achieves rebirth

Recently, Zoll announced that it has completed the previously announced acquisition of some assets of Vyaire Medical’s ventilator business. In August of this year, these two companies announced this transaction after Vyaire initiated Chapter 11 bankruptcy proceedings. Now that the dust has settled on the acquisition, Zoll will launch Vyaire’s Bellavista, Fabian, LTV, and 3100 HFOV series of ventilators, further expanding its respiratory care product line. It is worth mentioning that Vyaire was an important force in the supply of ventilators during the early stages of the COVID-19 pandemic, but applied for bankruptcy protection due to operational difficulties. And Medtronic also chose to withdraw due to the fact that its ventilator business is no longer profitable. Zoll’s acquisition undoubtedly brings new vitality and hope to the market. 01. The rise and fall of rising stars in ventilators Zoll stated that the acquired product line of ventilators and their related consumables, ...
- Source: drugdu
- 70
- October 18, 2024
A medical device enters the innovation channel

Recently, the Shanghai Medical Products Administration announced that in accordance with the requirements of the “Special Review Procedure for Class II Innovative Medical Devices in Shanghai”, the Shanghai Medical Products Administration has organized relevant experts to review the special review application for Class II innovative medical devices in the city, and intends to agree to allow Shanghai Futuo Zhida Medical Technology Co., Ltd. (hereinafter referred to as “Futuo Zhida”) to enter the special review procedure for its disposable pulmonary nodule three-dimensional identification positioning marker. Developing innovative technologies with AR navigation systems Founded in 2018, Futo Zhida is a subsidiary of Fosun Pharma, focusing on innovative medical devices and surgical development. Its team has rich experience and a global perspective in the development of image navigation algorithms, intervention consumables design, and production. According to the Chinese Journal of Tuberculosis and Respiratory Sciences, the incidence rate and mortality of lung cancer rank ...
- Source: drugdu
- 57
- October 18, 2024
Johnson & Johnson’s “Class 1 new drug for prostate cancer” approved for clinical trials in China

On October 12, according to the official website of CDE, Johnson & Johnson’s Class 1 new drug JNJ-78278343 injection obtained implicit approval for clinical trials and is suitable for the treatment of adult male patients with advanced prostate cancer. According to public information, JNJ-78278343 is a KLK2-CD3 bispecific antibody and T cell redirection product, which is designed to target KLK2 and induce T cell activation by binding to CD3 on T cells. This product has potential immunomodulatory and anti-tumor activity. After administration, it can bind to CD3 on T cells and KLK2 on tumor cells expressing KLK2, thereby redirecting T cells to tumor cells expressing KLK2, resulting in T cell-mediated lysis of KLK2-expressing tumor cells. At present, Johnson & Johnson has conducted a number of studies on JNJ-78278343 for prostate cancer internationally. Among them, the Phase 1 study of JNJ-78278343 monotherapy for advanced prostate cancer is expected to be initially ...
- Source: drugdu
- 61
- October 18, 2024
WuXi AppTec frequently mentioned this word during its Investor Day. Where does the confidence come from?

Recently, WuXi AppTec held an investor open day event called “CRDMO Ultimate Empowerment Journey”. At the event, WuXi AppTec executives mentioned the word “far ahead” many times. Although they said it with a calm face, the message they conveyed was “low-pitched and high-profile”, which won many applause and laughter from the audience. Why can they say that? Where does the confidence come from? If you really achieve “far ahead”, what is the secret? I just came back from WuXi AppTec’s investor day event, and I will highlight the key points for you. Both quantity and quality, the industry contribution is “far ahead” From the perspective of molecular types, the current research and development of small molecules is still the “main force” of current research and development and listing. Whether it is the number of drugs approved by the US FDA or the number of molecular pipelines under development, small molecules ...
- Source: drugdu
- 65
- October 18, 2024
Deepen the anti-corruption in the pharmaceutical industry and strictly prohibit 8 major behaviors

Another province issued compliance guidelines, 8 behaviors need to be closely watched. On October 14, the Jiangxi Provincial Market Supervision Administration issued the “Compliance Guidelines for Anti-Commercial Bribery in the Pharmaceutical Industry” (hereinafter referred to as the “Guidelines”), becoming another province to issue pharmaceutical compliance guidelines after Fujian and Chongqing. The “Guidelines” are divided into four chapters and 15 articles. The so-called pharmaceutical companies refer to operating entities engaged in the production, research and development, sales and other related commodities and related businesses of medical products such as drugs and medical devices, including but not limited to drug/medical device marketing authorization holders (MAHs), drug/medical device contract research organizations (CROs), drug/medical device contract manufacturing organizations (including CMOs, CDMOs), drug/medical device contract sales organizations (CSOs), and drug/medical device commercial distribution companies. Among them, 8 behaviors that may be suspected of commercial bribery are specifically listed, and pharmaceutical companies and medical and health ...
- Source: drugdu
- 65
- October 18, 2024
Zhan Jiufu talks about Sanming medical reform again

Some people introduce me as an expert and professor. I say I am nothing. This is not because I am modest, but because I seek truth from facts. I graduated from a normal school and don’t have much theory. I am just the actual operator of Sanming medical reform, at most a “construction team leader”. I put my energy into establishing Sanming medical reform, and I also established the Fujian Provincial Medical Insurance Office. Recently, the state has conveyed a lot of information about the Sanming medical reform experience. From the notice issued by the National Medical Insurance Bureau, the National Health Commission and other five ministries and commissions, to the National Medical Insurance Bureau’s release of documents in May, to the recent press conference held by the National Health Commission, stating that the Sanming medical reform experience will be implemented nationwide within 5 years… On September 27, I just ...
- Source: drugdu
- 53
- October 18, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.